Smiles
CC(C)(C)C(O[C@H]1[C@]2(C3=CC(CC4=CC=C(C=C4)OCC)=C(C=C3)Cl)O[C@@](CO2)([C@H]([C@@H]1OC(C(C)(C)C)=O)OC(C(C)(C)C)=O)COC(C(C)(C)C)=O)=O
Therapeutic Uses
Anti-Diabetic
Storage Condition
Refer MSDS for complete information
IUPAC Name
(1R,2S,3S,4R,5S)-5-(4-chloro-3-(4-ethoxybenzyl)phenyl)-1-((pivaloyloxy)methyl)-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triyl tris(2,2-dimethylpropanoate)
Synonyms
(1R,2S,3S,4R,5S)-5-(4-chloro-3-(4-ethoxybenzyl)phenyl)-1-((pivaloyloxy)methyl)-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triyl tris(2,2-dimethylpropanoate)
Application Notes
Useful research chemical for a range of applications
Hazard Compound
Refer MSDS for accurate information
Useful research chemical for a range of applications
Refund Policy
We are committed to offering products of the highest quality in order to meet the needs of our customers, and have elaborate systems in
place to ensure that material specifications, their certification and all handling and storage conditions are communicated at the time of
material handover.
We have invested in the highest quality packaging materials and use international logistics partners to service our customers. While all
possible precautions have been taken to deliver the required product(s), there may be some rare situations when our product does not
meet your requirements. Should that arise, please contact us with your concerns and we will endeavour to address them on a priority
basis. If there is no other option, we will either replace your product(s) or issue a refund or account credit, whichever you prefer.
If there is an issue with one or more of our products, our policy is that it must be reported to us within 45 days of your receiving shipment.
While we will always address product issues after the 45 day return window has passed, we cannot issue a refund or account credit. As
always, we appreciate your support.
Tetra-Pivaloyl ertugliflozin usage and description
Tetra-Pivaloyl ertugliflozin is a chemical compound used in the treatment of type 2 diabetes. It is a member of the SGLT2 inhibitor class of drugs, which work by inhibiting the function of the SGLT2 protein in the kidneys. This protein is responsible for reabsorbing glucose from the urine back into the bloodstream, which can lead to high blood sugar levels in people with diabetes. By inhibiting this protein, Tetra-Pivaloyl ertugliflozin helps to increase the amount of glucose that is excreted in the urine, thereby reducing blood sugar levels.
Chemically, Tetra-Pivaloyl ertugliflozin is a derivative of ertugliflozin, which is an SGLT2 inhibitor that was approved by the FDA in 2017. The addition of four pivaloyl groups to the ertugliflozin molecule increases its solubility and bioavailability, making it more effective at lower doses.
Tetra-Pivaloyl ertugliflozin is typically administered orally, in tablet form. It is important to follow the dosage instructions provided by a healthcare professional, as well as any other advice or recommendations regarding diet and exercise. As with all medications, there may be potential side effects associated with Tetra-Pivaloyl ertugliflozin, such as dehydration, urinary tract infections, and hypoglycemia. It is important to discuss any concerns or questions with a healthcare professional before starting treatment with this medication.
